NetworkNewsBreaks – Delic Holdings Corp. (CSE: D
Post# of 135
Delic Holdings (CSE: DELC) (OTCQB: DELCF) understands the potential of the psychedelic industry in regard to health care. While in its early stages, the industry is estimated to grow tremendously, and Delic seeks to capitalize on the sector’s potential to not only benefit millions of people dealing with mental health issues, but also create value for its shareholders. “Delic is banking on scientific research to prove the usefulness and effectiveness of psychedelics as an alternative treatment for specific mental health conditions. It also relies on customer feedback to help push the conversation and further increase the sensitization of psychedelics for mental health conditions,” a recent article reads. A survey conducted on Delic’s behalf by The Harris Poll noted that a majority of Americans who deal with PTSD/depression/anxiety (65%) believe that psychedelic medicine should be available to patients with treatment-resistant conditions. “Already, policy toward psychedelics in the health care space is evolving. Legislative and regulatory changes are slowly coming into effect, allowing the psychedelic industry to grow and achieve its full potential. Delic seeks to capitalize on this to grow its brand and define its position in the global psychedelics space.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer